

REMARKS

The disclosure was objected to because the structures of the compounds in the table from pages 175-433 were too small to be legible.

Applicants attach hereto revised pages 175-448, which correspond to original compound structures found on pages 175-433. No new matter is added by these revised compound structures which were merely reproduced at a larger resolution.

Conclusion

Applicant respectfully requests reconsideration and withdrawal of the outstanding objection, in light of the foregoing amendments and remarks.

Respectfully submitted,

Date:

April 27, 2004

Keith D. Hutchinson

Keith D. Hutchinson
Attorney For Applicant
Registration No. 43,687

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 526-4608
Fax: (858) 678-8233